酸乙和认知障碍在CKD中的关联
Hélène Levassort1,2, Julie Boucquemont2, Sophie Liabeuf3,4
1Geriatric Department, University Medical Department 1, AP-HP, Ambroise Paré Hospital, University Hospital Group Pais Saclay, Boulogne-Billancourt, France.
Kidney international reports
|August 15, 2025
概括
高甲基氨酸 (PAG) 水平与慢性脏病 (CKD) 的成年人认知障碍有关. 这项研究确定PAG是一种潜在的尿性毒素,有助于CKD患者的认知能力下降.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 神经学 神经学
- 毒理学 毒理学 毒理学
背景情况:
- 慢性病 (CKD) 与由于尿路毒素 (UT) 积累的认知障碍 (CI) 有关.
- 乙谷氨 (PAG) 已成为一种潜在的UT,可以将CKD和CI联系起来.
- 在非透析依赖的CKD患者中,PAG和CI之间的关联仍未得到充分研究.
研究的目的:
- 研究非透析依赖性慢性瘤的成年人血清PAG水平和认知障碍 (CI) 之间的关联.
- 确定PAG作为潜在的尿性毒素,有助于该人口的认知能力下降.
主要方法:
- 从CKD-脏流行病学和信息网络 (CKD-REIN) 队列中对2590名患者进行横截面分析.
- 认知障碍被定义为迷你精神状态考试 (MMSE) 的得分≤26.
- 后勤回归用于评估PAG水平和CI之间的关联,以多个共变量进行调整.
主要成果:
- 35%的患者 (908/2590) 呈现认知障碍 (MMSE ≤26).
- 在调整后,血清PAG水平增加2倍显著与认知障碍相关 (OR [95% CI]:1.12 [1.01-1.23]).
- 在考虑到社会人口统计学因素,心血管风险和其他尿道术后,这种关联仍然存在.
结论:
- 血清PAG水平升高与非透析依赖的CKD成年人的认知障碍有关.
- PAG被强调为一种新型尿性毒素,可能导致CKD的认知功能障碍.
- 需要进一步的研究来确认因果关系,并探索用于认知保护的PAG降低策略.
相关概念视频
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
206
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
206
01:24Chronic Kidney Disease II: Clinical Manifestations
91
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
91
01:25Chronic Kidney Disease I: Introduction
67
Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
67
01:28Chronic Kidney Disease III: Interprofessional Care
80
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
80
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention
57
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
57
01:22Alzheimer's Disease: Treatment
261
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
261